Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion …
K Tamura, J Tsurutani, S Takahashi, H Iwata… - The Lancet …, 2019 - thelancet.com
Background Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody–drug
conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and potent …
conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and potent …
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer …
…, O Akihiko, S Yasuaki, S Eiji, T Masato, T Yuko, T Kenji… - The Lancet, 2020 - thelancet.com
Background Pembrolizumab monotherapy showed durable antitumour activity and manageable
safety in patients with metastatic triple-negative breast cancer. We aimed to examine …
safety in patients with metastatic triple-negative breast cancer. We aimed to examine …
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind …
…, AP Aparicio, LV Boixader, C Scott, K Tamura… - The lancet …, 2017 - thelancet.com
Background Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown
efficacy in a phase 2 study when given in capsule formulation to all-comer patients with …
efficacy in a phase 2 study when given in capsule formulation to all-comer patients with …
[HTML][HTML] Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
…, YH Park, SB Kim, K Tamura… - … England Journal of …, 2020 - Mass Medical Soc
Background Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed
of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable …
of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable …
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis …
…, A Baldoni, TW Park-Simon, K Tamura… - The Lancet …, 2021 - thelancet.com
Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
been shown to extend progression-free survival versus placebo when given to patients with …
been shown to extend progression-free survival versus placebo when given to patients with …
Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells
…, R Takahashi, M Yoshida, H Tsuda, K Tamura… - Science …, 2014 - science.org
Breast cancer patients often develop metastatic disease years after resection of the primary
tumor. The patients are asymptomatic because the disseminated cells appear to become …
tumor. The patients are asymptomatic because the disseminated cells appear to become …
[HTML][HTML] Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood–brain barrier
…, M Ono, T Katsuda, Y Yoshioka, K Tamura… - Nature …, 2015 - nature.com
Brain metastasis is an important cause of mortality in breast cancer patients. A key event
during brain metastasis is the migration of cancer cells through blood–brain barrier (BBB). …
during brain metastasis is the migration of cancer cells through blood–brain barrier (BBB). …
[HTML][HTML] Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low–expressing advanced breast cancer: results from a phase Ib study
…, H Park, RK Murthy, H Iwata, K Tamura… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human
epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a …
epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a …
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Background Pembrolizumab showed durable antitumour activity and manageable safety in
metastatic triple-negative breast cancer in the single-arm KEYNOTE-012 and KEYNOTE-086 …
metastatic triple-negative breast cancer in the single-arm KEYNOTE-012 and KEYNOTE-086 …
Predictive factors for interstitial lung disease, antitumor response, and survival in non–small-cell lung cancer patients treated with gefitinib
…, N Yamamoto, K Takeda, K Tamura… - Journal of Clinical …, 2006 - ascopubs.org
Purpose Interstitial lung disease (ILD) is a serious adverse effect of gefitinib, but its prevalence
and risk factors remain largely unknown. We examined the prevalence of and risk factors …
and risk factors remain largely unknown. We examined the prevalence of and risk factors …